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ABSTRACT
Purpose: pancreatic adenocarcinoma is the fourth leading cause of cancer 
related deaths due to its aggressive behavior and poor clinical outcome. There is a 
considerable variability in the frequency of serum tumor markers in cancer’ patients. 
We performed a metabolomics screening in patients diagnosed with pancreatic 
cancer.
Experimental Design: Two targeted metabolomic assays were conducted on 40 
serum samples of patients diagnosed with pancreatic cancer and 40 healthy controls. 
Multivariate methods and classification trees were performed.
Materials and Methods: Sparse partial least squares discriminant analysis 
(SPLS-DA) was used to reduce the high dimensionality of a pancreatic cancer 
metabolomic dataset, differentiating between pancreatic cancer (PC) patients 
and healthy subjects. Using Random Forest analysis palmitic acid, 1,2-dioleoyl-
sn-glycero-3-phospho-rac-glycerol, lanosterol, lignoceric acid, 1-monooleoyl-
rac-glycerol, cholesterol 5`,6` epoxide, erucic acid and taurolithocholic acid 
(T-LCA), oleoyl-L-carnitine, oleanolic acid were identified among 206 metabolites 
as highly discriminating between disease states. Comparison between Receiver 
Operating Characteristic (ROC) curves for palmitic acid and CA 19-9 showed that 
the area under the ROC curve (AUC) of palmitic acid (AUC=1.000; 95% confidence 
interval) is significantly higher than CA 19-9 (AUC=0.963; 95% confidence 
interval: 0.896-1.000).
Conclusion: Mass spectrometry-based metabolomic profiling of sera from 
pancreatic cancer patients and normal subjects showed significant alterations in the 
profiles of the metabolome of PC patients as compared to controls. These findings 
offer an information-rich matrix for discovering novel candidate biomarkers with 
diagnostic or prognostic potentials.
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INTRODUCTION
Pancreatic cancer (PC) is the fourth leading cause of 
cancer related deaths in the western world [1]. Due to the 
absence of early symptoms, the lack of effective systemic 
therapies and its aggressiveness, pancreatic cancer is 
characterized by a poor prognosis with only less than 5% 
of PC patients surviving up to 5 years [2].
The high morbidity and mortality associated with 
PC determine an urgent need for diagnostic biomarkers, 
as best approach to alert for this malignancy. Nowadays, 
the carbohydrate antigen CA 19-9 represents the most 
useful biochemical marker to distinguish PC patients from 
non-cancerous conditions, and to monitor PC recurrence 
following surgery [3]. However, different studies have 
been performed in the attempt to discover and improve 
minimally invasive and early diagnostic tools for PC, 
and several alternative tissues, serum and stool potential 
biomarkers have been proposed [4]. Tissue markers 
include genetic alterations of KRAS, p16/CDKN2A, 
TP53, SMAD4, that, in association with RNF43 and 
GNAS genes mutations, occur with high frequency also in 
PC precursor lesions [5, 6]. Alternative serum biomarkers 
emerged during the last decades, such as inhibitory 
cytokine-1 (MIC-1), CEACAM1, osteopontin (OPN), 
MUC-1, HSP70 and ULBP2 [7-12], and panels of other 
emerging serum markers, capable of discriminating PC 
patients from healthy subjects, have been also reported [7]. 
Similarly, a number of evidences highlighted alteration of 
specific microRNAs expression as promising blood- and 
tissue-based biomarkers for PC [13], and the aberrant 
methylation of BMP3 gene was suggested as a stool 
marker for PC patients compared to healthy controls [14].
Recently scientists are taking advantage of 
metabolomics approaches in order to have a complete 
picture of biological cells, tissue and organs to try to 
find new biomarkers [15]. As altered metabolite profiles 
are associated with disease, metabolomics approach 
represent an additional opportunity and a powerful 
tool to detect perturbations in the metabolome. In 
this study we performed a metabolomic screening in 
patients diagnosed with pancreatic cancer and in healthy 
controls.
RESULTS
Inter-class diversity assessment of metabolite 
profiles
Inter-class diversity was assessed by principal 
component analysis. Figure 1A (different classes of 
lipids) shows how ellipsoids grouping samples that belong 
to same classes are far away from each other, thereby 
indicating a net diversity between classes. Metabolite 
Figure 1: Principal component analysis 3D plots of LIPIDS (left) and metabolic profile (right) data sets. 3D representation 
of patients, grouped by disease state. Blue dots are diseased patients, while red dots are healthy patients. The first three components are 
represented by the axes of the plot and capture the most variance of the data.
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profiles analyzed by the biocrates kit were quite of 
minor differentiating ability between groups (Figure 
1B), still lying on orthogonal semi axes. However, this 
was indicative of the presence of a differential set of 
metabolites between diseased and healthy subjects.
Consensus-based metabolites selection
We selected 16 metabolites, listed in Table 1, by 
intersecting the results of the three above-mentioned 
methods and then performed a hierarchical clustering 
(Figure 2). Four of these metabolites showed the highest 
cooperative discriminant potential, even though at a 
different extent: palmitic acid and oleanolic acid were the 
most perturbed metabolites. D-sphingosine and T-CDCA 
(taurochenodeoxycholate) were mildly discriminating 
factors. T-CDCA, in particular, was up-regulated in a few 
tumor patients (Figure 3). Metabolites were then subjected 
to functional enrichment analysis by Ingenuity Pathway 
Analysis. Over-represented functions were mostly correlated 
with pancreatic cancer onset/progression. As shown in 
Figure 4, palmitic acid and D-sphingosine modulate cell 
viability, apoptosis, cell cycle, migration and invasion in 
the frame of pancreatic cancer. Green color means down-
regulation, red up-regulation of the four metabolites (small 
circles). Octagons represent relevant functions, which might 
be inhibited - if colored in blue - or activated - if colored in 
orange -, according to the up-regulation or down-regulation 
levels of the connected metabolites.
Results from random forest: selection of the top 
discriminating metabolites
We run RF analysis by randomly selecting 20 
metabolites as candidates for each node split of each 
tree included into the forest. The number of selected 
metabolites is the only user-required parameter of the RF 
and the choice of such metabolites randomly varies from 
tree to tree. By default, an acceptable value is represented 
by the square root of the number of metabolites. As the 
total number of metabolites was 206, we should select at 
least 14 metabolites and, indeed, we arbitrary decided to 
be more conservative and select 20 metabolites, which 
represented about 10% of the total number of metabolites. 
Figure 5 depicts the importance values of the top 25 
metabolites (from the most to the less relevant). Medians 
of metabolite levels in patients with pancreatic cancer 
and in healthy donor were reported in Supplementary 
Table 1 whilst the full list of variable importance for all 
metabolites was further reported in Supplementary Table 
2. We found that palmitic acid, 1,2-dioleoyl-sn-glycero-
3-phospho-rac-glycerol, lanosterol, lignoceric acid, 
monooleoyl-rac-glycerol, cholesterol 5α,6α epoxide, 
erucic acid, T-LCA, oleoyl-L-carnitine, oleanolic acid 
clearly achieved the highest importance values than all 
other metabolites.
Table 1: List of 16 metabolites obtained by intersecting the results of sPLS-DA, Greedy stepwise and Genetic Search 
analyses
Metabolites Which sPLS-DA Component
Lysophosphatidylcholine C16:0 1
Lysophosphatidylcholine C18:0 1
Phosphatidylcholine (32:1) 1
Cholesterol 5α,6α epoxide 2
1,2-dioleoyl-sn-glycero-3-phospho-rac-glycerol 1
D-sphingosine 1
Lanosterol 1
Erucic acid 1
Palmitic acid 1
Behenic acid 1 and 2
Lignoceric acid 1
Oleanolic acid 1
Glyceryltrilinoleate 1
1-monooleoyl-rac-glycerol 1 and 3
Glycolithocholic acid -
Taurochenodeoxycholic acid 3
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Results from ROC curve analysis: 
discriminatory power of the top discriminating 
metabolites
The estimation of the AUC was performed for all 
metabolites and results were reported in Supplementary 
Table 3. As shown, for each metabolite, the best threshold 
(cut-off), at which sensitivity and specificity were 
jointly maximized was further reported. As shown, all 
metabolites previously found at the RF analysis (i.e., 
palmitic acid, 1,2-dioleoyl-sn-glycero-3-phospho-rac-
glycerolcholesterol 5α,6α epoxidelanosterol, lignoceric 
acid, 1oleoyl_rac_GL, cholesterol_epoxide, erucic acid, 
T-LCA, oleoyl-L-carnitine, oleanolic acid) achieved the 
highest discriminatory power (AUC=1.00, 95%CI: 1.00-
1.00), suggesting that all the estimated cut-offs points 
perfectly discriminate patients form healthy controls.
CA19.9 vs palmitic acid as tumor 
discriminant marker
Tumor markers including carcinoembryonic 
antigen (CEA) or carbohydrate antigen 19-9 (CA19-
9) are frequently determined at the time of diagnosis in 
patients with pancreatic cancer. To date, CA19-9 is the 
only biomarker routinely used, and FDA approved, for 
the clinical management of PC. Although several studies 
indicated a suboptimal prognostic relevance of this 
marker in pancreatic cancer, due to its low sensitivity and 
specificity [3], it has certain limitations in diagnosis and 
for screening purposes of the population at risk, which 
results in a difficult task to distinguish pancreatic cancer 
from benign tumors with normal CA19-9.
Among all screened metabolites, we found that 
palmitic acid achieved the highest discriminatory power to 
distinguish PC patients from healthy controls. It was also 
used to investigate its prognostic ability in comparison to 
the baseline levels of CA 19-9. Plots of the ROC curves 
and the boxplots of metabolite levels were reported in 
Figure 6 for palmitic acid (upper left and upper right) and 
for CA 19-9 (bottom left and bottom right), separately. We 
found that the AUC for CA 19-9 was 0.963, along with 
a 95%CI of 0.896-1.000. The best threshold was found 
at the value of 55.59 μM, where CA 19-9 achieved a 
sensitivity of 92.6% and a specificity of 100%. Similarly, 
the AUC for palmitic acid was 1.000, along with a 95%CI 
of 1.000-1.000. The best cut-off was found at the value of 
134.38 μM, where palmitic acid achieved a sensitivity of 
100% and a specificity of 100%.
Figure 2: Hierarchical clustering for the 16 selected metabolites listed in Table 1. 
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DISCUSSION
Along with multiple genetic, epigenetic, and 
growth signaling alterations, cancer cells reprogram 
several metabolic pathways [16, 17]. Therefore in the 
cancer research field, metabolomics studies may lead to 
an enhanced understanding of disease mechanisms and to 
the discovery of new diagnostic biomarkers; they may also 
improve understanding of mechanisms for drug efficacy 
with the intent to tailor the therapeutic regimen to the 
individual patient.
Several reports suggested various potential 
biomarkers for pancreatic cancer in pancreatic 
tissue, such as leucine, isoleucine, valine, lactate, 
alanine, phosphocholine, glycerophosphocholine, 
taurine, and betaine [18]; taurine, lactate, creatine, 
and glutamate [19], in serum (3-hydroxybutyrate, 
3-hydroxyisovalerate, lactate, trimethylamine-N-
oxide, isoleucine, triglyceride, leucine, and creatine 
[20]; glutamate, acetone, 3-hydroxybutyrate, 
glucose, phenylalanine, formate, mannose, ethanol, 
asparagine, creatine, proline, and glycerol, plasma 
(N-methylalanine, lysine, glutamine, phenylalanine, 
arachidonic acid, lysophosphatidylcholine (18:2), 
phosphatidylcholine (34:2), phosphatidylethanolamine 
(26:0), tauroursodeoxycholic acid, taurocholic 
acid, deoxycholylglycine, and cholylglycine) [21], 
in urine (acetoacetate, citrate, creatinine, glucose, 
glycine, hippurate, 3-hydoxyisovalerate, leucine, 
2-phenylacetamide, and trigonelline [15], and in saliva 
(leucine, isoleucine, tryptophan, valine, glutamate, 
phenylalanine, glutamine and aspartate) [22].
Perturbations of several metabolic pathways 
including glycolysis, amino acid metabolism, nucleotide 
and glycerophospholipid metabolism with increased 
fatty acid synthesis and changes in fatty acid metabolism 
Figure 3: Star plots for four most discriminating metabolites. Blue lines are related to tumor samples. Red lines refer to control 
samples. Radius increases with metabolite levels.
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Figure 4: Metabolites involvement in critical functions and pathways related to the cancer onset/progression. Green 
color means down-regulation, (light) red up-regulation of the four metabolites (small circles). Octagons represent relevant functions, which 
might be inhibited - if colored in blue - or activated - if colored in orange -, according to the up-regulation or down-regulation levels of 
the connected metabolites. Activation or inhibition states are inferred by literature evidences (PMIDs: 14688288, 24648512, 17440087, 
12524422, 12810709).
Figure 5: Variable importance values of the top 25 metabolites (from the most to the less important).
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have been proposed as determinants of the onset and 
progression of pancreatic cancer [23].
Free fatty acids, are relevant mediators of the 
proinflammatory milieu [24] and specifically the saturated 
free fatty acid palmitate, correlate positively with 
concentrations of the proinflammatory cytokine IL-6 [25].
Moreover, experimental studies have suggested 
that polyunsaturated fatty acids (PUFAs), but not 
monounsaturated (MUFAs) or saturated fatty acids 
(SFAs), inhibit human pancreatic cancer cell growth, 
which indicate the relationship between fats consumption 
and risk of pancreatic cancer may rely on the level of 
specific fatty acids intake [26, 27]. SFA promotes insulin 
resistance, whereas MUFA and PUFA improve insulin 
resistance [28], which might be involved in pancreatic 
cancer development [28, 29] such as in other types of 
cancer [30].
The excess of saturated free fatty acids, such as 
palmitic acid, that induces lipotoxicity in hepatocytes, has 
been implicated in the development of non-alcoholic fatty 
liver disease also associated with insulin resistance. In 
human and mouse hepatocytes palmitic acid, at a lipotoxic 
concentration, triggers early activation of endoplasmic 
reticulum (ER) stress-related kinases, inducing the 
apoptotic transcription factor CHOP, activating caspase 
3 and increases the percentage of apoptotic cells. These 
effects concurred with decreased IR/IRS1/Akt insulin 
pathway [31]. In the present study, the concentrations of 
palmitic acid were 20 times lower in pancreatic cancer 
patients than healthy subjects, whereas oleanolic acid 
levels were 10 times higher in PC than control group 
Figure 6: ROC curves and the boxplots of metabolite levels for palmitic acid (upper left and upper right) and for CA 
19-9 (bottom left and bottom right).
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(Supplementary Table 1). In addition by Ingenuity 
Pathway Analysis the same metabolites resulted as 
mostly perturbed with the highest discriminatory power 
(AUC=1.00, 95%CI: 1.00-1.00) between the patients and 
controls.
In addition, animal models have shown that 
saturated free fatty acids preferentially upregulate the 
production of proinflammatory cytokines (including 
TNF-α and IL-6) via mechanisms mediated in part 
through the Toll-like receptor 4/nuclear factorkB pathway 
[32, 33]. Furthermore, free fatty acids are an important 
source of reactive oxygen species through increased 
lipid peroxidation and correlate positively with increased 
plasma concentrations of the proinflammatory adipokine 
leptin [34].
In previous studies, human serum extracts enriched 
for selected hydroxylated polyunsaturated ultra long-
chain fatty acids (GTAs) resulted to protect against 
inflammation through the down-regulation of NFκB and 
several pro-inflammatory markers in both human colon 
cancer and RAW264.3 mouse macrophage cells exposed 
to lipopolysaccharide [35]. GTA-treated cells also showed 
reduced proliferative capacity through a pro-apoptotic 
mechanism [35]. In colon cancer, for example, low-
serum concentrations of GTA-446, an anti-inflammatory 
polyunsaturated long-chain fatty acid, was proposed by 
Ritchie and colleagues as a new risk factor [36]. Moreover 
GTAs act analogously to the resolvins and protectins [37], 
protecting the body against the accumulation of chronic 
inflammation over time. Compromised levels with age are 
suspected to favor the establishment of a pro-inflammatory 
environment, and ultimately lead to the DNA damage 
observed in many tumors.
Ritchie and colleagues [23], using a non-targeted 
metabolomics approach based on high-resolution, flow-
injection Fourier transform ion cyclotron resonance mass 
spectrometry (FI-FTICR-MS), generated comprehensive 
metabolomic profiles from the serum of PC patients and 
disease-free subjects, isolating than the high discriminating 
ability of PC-594 metabolite between PC and healthy 
subjects. The latest recent findings by Ritchie and co-
workers, who evaluated the potential clinical benefit of 
screening based on PC-594 to identify subjects with PC 
or a high-risk of developing PC, suggested that PC-594, 
belonging to the same metabolic system as GTA-446, 
could be involved in inflammatory processes of subjects 
with chronic pancreatitis and could be causally involved 
in the establishment of PC [36].
Lastly, palmitic acid is cytotoxic to β-cells in models 
of obesity and diabetes, as well as normal β-cells [38] and 
has been shown to induce apoptosis in exocrine pancreatic 
AR42J cells [39].
In the present study, the concentrations of palmitic 
acid were 20 times lower in pancreatic cancer patients 
than healthy subjects, whereas oleanolic acid levels were 
10 times higher in PC than control group (Supplementary 
Table 5). In addition by Ingenuity Pathway Analysis the 
same metabolites resulted as mostly perturbed with the 
highest discriminatory power (AUC=1.00, 95%CI: 1.00-
1.00) between the patients and controls.
The relative variable importance (VIMP) ranking 
values from RF analysis were for palmitic acid and 
oleanolic acid, respectively, of 100% and 95.3% 
(Supplementary Table 2), showing a clear predictive 
potential and a substantial larger importance of the two 
metabolites in respect to all others.
Oleanolic acid (OA) belongs to the triterpenoids 
family and is widely distributed in the skin and seeds 
of different edible fruits, including olives and white or 
red grapes, fruits and some medicinal herbs and it has 
been reported to have antioxidant, anti-inflammatory, 
antidiabetic, antimutagenicity and recently, anti-tumor 
activity for its marked effects and low toxicity [40].
The traditional Mediterranean diet, characterized 
by the consumption of foods such as grapes, wine, must, 
raisins, olives and virgin olive oil, has been associated 
with a low incidence of cancer [41]. Previously, it has been 
described that oleanolic acid and palmitic acid possess 
cardioprotective effects [42, 43], anti-inflammatory effects 
[44], and antiproliferative effects in highly invasive cancer 
cells and induce apoptosis in a wide variety of tumor cells 
including human prostate cancer cells [45], hepatocellular 
carcinoma cells [46], human pancreatic cells [47], liver 
cancer, lung cancer, osteosarcoma cells, human leukemia 
cells, human melanoma cells and colon cancer cells, 
among others [48].
OA in particular, could have potential 
chemopreventive activity in human breast cancer [49]: at 
low concentrations, it is a natural compound that acts as an 
antioxidant and prevents oxidative DNA damage in human 
mammary epithelial cells.
Recently, the anti-tumor activity of oleanolic acid 
has attracted much attention for its marked effects and 
low toxicity. OA can be also synthetized by humans 
as autodefense mechanisms. Several studies have 
shown that this metabolite could inhibit proliferation 
and induce apoptosis in a wide variety of tumor cells 
including colon cancer, breast cancer, liver cancer, lung 
cancer, osteosarcoma cells, human leukemia cells and 
human melanoma cells. Recently, Wei and colleagues 
have examined the anti-tumor activity of oleanolic 
acid on pancreatic cancer cells. The results of these 
studies provide evidence that it is able to arrest the cell 
cycle and induce apoptosis, possibly via ROS-mediated 
mitochondrial, and lysosomal pathway in Panc-28 cells, 
which resulted reversible by using the ROS scavenger 
vitamin C [47]. The expression of apoptosis-correlated 
proteins was also affected in cells exposed tooleanolic 
acid, including activation of caspases-3/9 and cleavage of 
PARP [50].
Further study revealed others mechanism of action 
of oleanolic acid, such as mitochondrial depolarization, 
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release of cytochrome C, lysosomal membrane 
permeabilization and leakage of cathepinB [47].
MS-based lipidomic analysis of sphingolipids 
from metastatic pancreatic tissues revealed discrete and 
significant changes in specific ceramide molecule as 
compared to either pancreatic cancers without metastases 
or non-cancerous pancreatitis specimens [51]. Sphingosine 
and sphingosine-1-phosphate (S1P) manifest diverse 
biological, biochemical and biophysical functions 
that mediate, in part, cellular proliferation, migration, 
tumorigenesis, apoptosis and inflammation [52, 53] and 
are implicated in tumor growth of pancreatic stellate cells 
[54]. Mechanistically, sphingosine and S1P are typically 
considered pro-inflammatory, pro-mitogenic, and/or 
chemotaxic lipids that may facilitate the progression of 
pancreatic cancer, and it has been recognized and accepted 
by most researchers that sphingosine kinase acts like an 
oncogene and is upregulated in many human cancers [55]. 
Out of three sphingolipids included in our study one was 
sphingosine which resulted significantly higher (0.24±0.04 
μM, mean±SD) in PC patients than normal controls 
(0.09±0.08 μM, mean±SD). Our data were keeping with 
a previous study performed by Jiang et al., who reported 
elevated levels in plasma of PC subjects of ceramide 
metabolites, including phosphorylated (sphingosine- and 
sphinganine-1-phosphate) and glycosylated (cerebroside) 
species [51]. The deregulation of sphingolipid metabolism 
was associated with more advanced and aggressive 
behavior of the cancer. The estimation of the Area Under 
the Curve (AUC) for sphingosine was 0.942 (0.877-
1.000) (95%CI), showing a good sensitivity (92.5%) and 
specificity (97.5%) in the discrimination between healthy 
controls and pancreatic cancer patients.
It is well known that, to fulfill the increased energy 
requirements, pancreatic tumor cells secrete cytokines/
factors inducing muscle and fat degradation in PC patients, 
a condition known as cancer cachexia. A high-fat and low-
carbohydrate diet that elevates circulating levels of ketone 
bodies (i.e., acetoacetate, β-hydroxybutyrate, and acetone) 
diminish the overall energetic health of pancreatic cancer 
cells by reducing glucose uptake, lactate release, glutamine 
uptake, cellular ATP content, and ROS levels [56].
Epidemiological studies have demonstrated a 
positive correlation between ingestion of a western-style 
high fat diet and the incidence of pancreatic cancer [57].
Diets with a high fat content stimulate bile secretion, 
which increases the availability of cholesterol, bile acids 
and their metabolites.
Pancreatic cancer frequently causes obstructive 
jaundice and elevates bile acid levels in serum. Bile 
acids are steroid metabolites of cholesterol functioning 
as trophic factors for gut epithelium and as detergents 
for absorption of cholesterol and fat-soluble vitamins. 
Cytotoxicity of bile acid stems from its hydrophobic 
features and hydrophobic-hydrophilic balance in serum. 
Lipophilic unconjugated bile acids have been shown to 
flip-flap rapidly across artificial lipid bilayers, so that 
unconjugated bile acids might enter the cytosol of cells 
even at a low concentration. It has also been demonstrated 
that chenodeoxycholic acid (CDCA) administration in rat 
colon could enhance cell membrane phospholipid turnover 
[58], showing a significant increase of glycine and 
taurine conjugates species in patients with extrahepatic 
cholestasis. Finally, hydrophobic bile acids, such as DCA, 
could damage cells by lysing membranes and impairing 
mitochondrial function as well as increasing the generation 
of reactive oxygen radicals which can cause membrane 
lipid peroxidation and attack nucleic acids. The metabolic 
analysis in our investigation indicated that free bile 
acids in plasma of PC patients were significantly lower 
than controls. Instead, the concentrations of conjugated 
(glycine and taurine) cholic and chenodeoxycholic acids 
were significantly higher in PC group than controls, 
resembling the elevation of some bile acids in jaundiced 
serum of PC subjects that seems to inhibit pancreatic cell 
growth and proliferation [59].
In summary our mass spectrometry-based 
metabolomic profiling of pancreatic cancer patients and 
normal subjects allowed us to identify four metabolites 
(oleanoic acid, palmitic acid, taurochenodeoxycholate 
and d-sphingosine) with highly discriminative potential. 
Palmitic acid has a better discriminating ability in 
comparison to the pretherapeutic tumor marker CA 19-9 
suggesting that, the joint evaluation of both pretherapeutic 
tumor markers CA19-9 and palmitic acid levels should 
be recommended in order to significantly reduce the 
probability to detect false positives and it could be used 
to improve the prognostic prediction in patients with 
pancreatic cancer.
MATERIALS AND METHODS
Patients and outline of the study
Forty patients with a confirmed diagnosis of PDAC 
and forty healthy blood donors (controls), referred to the 
“Casa Sollievo della Sofferenza” Hospital of San Giovanni 
Rotondo, Italy, were enrolled in the study. All patients 
signed an informed consent approved by the local Ethics 
Committee. The consent included collection of serum 
sample and clinical-pathological patient’s features. The 
latter are reported in the Table A of the twin paper [69]. 
50μl of serum sample was available for each subjects, 
two different but complementary targeted metabolomics 
approaches (commercial and custom-made quantitative 
methods) were used in order to analyze a large number of 
polar and hydrophobic metabolites in serum samples of 
healthy and pancreatic cancer’ patients. The first one was 
a combination of direct injection and LC-MS/MS assay 
(Absolute IDQ p180 kit, Biocrates Life Sciences AG, 
Innsbruck, Austria) for the analysis of amino acids and 
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biogenic amines, acylcarnitines, glycerophospholipids and 
hexoses. The second one was a “custom made” LC-MS/
MS assay for the analysis of bile acids, fatty acids, sterols, 
glycerolipids, glycerophospholipids and sphingolipids. All 
details about preparation of standard solutions, validation 
of the method and instrumental parameters are described 
in the Supplementary Electronic Material (Supplementary 
Table 4-7).
Chemicals and reagents
The AbsoluteIDQ® p180 Kit was purchased 
from Biocrates Life Sciences AG, Innsbruck, Austria. 
All chemical standards of lipids were purchased from 
Aldrich-Fluka-Sigma S.r.l. (Milan, Italy). Labeled internal 
standards: D3-octanoyl L-carnitineHCl, D3-hexadecanoyl 
L-carnitineHCl, D3-acetyl L-carnitineHCl, D3-L-carnitine 
HCl, D3-eicosanoic acid, D3-octadecanoic acid (D3-
stearic acid) and D3-tetradecanoic acid (D3-myristic 
acid) were from CDN Isotope (Quebec, Canada); D7-
cholesterol, D4-cholic acid, D4-chenodeoxycholic acid, 
D4-glycoursodeoxycholic acid, D4-glycocholic acid, D5-
taurocholic acid, D5-taurodeoxycholic acid, D4-lithocholic 
acid were from Sigma–Aldrich (Sigma–Aldrich, Milan, 
Italy). All chemicals had a purity grade greater than 90% 
and were used without further purification. Acetonitrile 
(ACN), 2-propanol (IPA), methanol (CH3OH), chloroform 
(CHCl3) and triethylamine (TEA) were purchased from 
Sigma–Aldrich (Sigma–Aldrich, Milan, Italy). All 
these solvents were of LC-MS grade, water was MilliQ 
(Millipore, Vimodrone, Milan, Italy). Formic acid 
(HCOOH) and ammonium formate (NH4COOH) additive 
for LC–MS were from FLUKA (Sigma–Aldrich, Milan, 
Italy).
Metabolomic measurements by Biocrates kit
The serum samples, from patients and controls, 
were collected after an overnight fast and stored in 
-80°C till analysis. A targeted metabolomic assay was 
performed in samples of serum from pancreatic cancer 
patients and healthy control subjects (n=80) using the 
BiocratesAbsoluteIDQ® p180 Kit (BIOCRATES life 
Sciences AG, Innsbruck, Austria), as previously described 
[60, 61]. Briefly, the flow injection analysis (FIA) tandem 
mass spectrometry (MS/MS) method was used to quantify 
180 known small molecule metabolites simultaneously by 
multiple reaction monitoring (MRM) using an Acquity 
UPLC chromatographic system (Waters, Millford, MA, 
USA) coupled with a Xevo TQ-MS mass spectrometer 
(Waters, Millford, MA, USA). Quantification of the 
metabolites was achieved by reference to appropriate 
internal standards. Reproducibility of the assay was 
performed on QC serum samples. Concentrations of 
all analysed metabolites were reported in μM. The 
metabolomics dataset contains 40 acylcarnitines 
(Cx:y), hydroxylacylcarnitines(C(OH)x:y) and 
dicarboxylacylcarnitines (Cx:y-DC); 40 amino acids and 
biogenic amines; one sugar; 10 sphingomyelins (SMx:y) 
and sphingomyelin-derivatives (SM(OH)x:y); and 90 
glycerophospholipids (PC). Glycerophospholipids are 
differentiated with respect to the presence of ester (a) and 
ether (e) bonds in the glycerol moiety, where two letters 
(aa = diacyl, ae = acyl-alkyl) denote that two glycerol 
positions are bound to a fatty acid residue, while a single 
letter (a = acyl) indicates the presence of a single fatty 
acid residue. Lipid side chain composition is abbreviated 
as Cx:y, where x denotes the number of carbons in the 
side chain and y the number of double bonds. The full list 
of metabolites is presented in the supplementary material 
(Supplementary Table 1).
Targeted lipids analysis
An Ostro™ 96-well plate (Waters, Milford, 
MA, U.S.A.) was used to extract from human sera of 
a series of metabolites belonging to different classes 
of lipids: bile acids, fatty acids, sterols, glycerolipids, 
glycerophospholipids and sphingolipids.
The sera samples (50 μL) were loaded into the well 
plate and spiked with two internal standard solutions 
(50 μL of 50 μM of labeled bile acids and 10 μL of 500 
μM of labeled lipids), mixed with 500 μL of acetonitrile 
with 0.1% formic acid (v/v) and transferred to a 96-well 
vacuum manifold where vacuum suction was applied for 
extraction. It took less than 3 min for the precipitated 
sample to completely pass through the packed bed. This 
procedure was repeated twice. The resulting eluent was 
collected in a 96-well collection plate and dried using 
N2 gas at 40°C, and finally reconstituted in 50 μL of 
MeOH:H2O 50:50 (v/v). The precipitated material into 
the well plate was washed twice with 800μL of a solution 
of MeOH:CHCl3:TEA (45:45:10, v/v/v) and transferred 
to a 96-well vacuum manifold where vacuum suction 
was applied for the elution of the phospholipids retained 
in the first step. The resulting eluent was collected in a 
96-well collection plate and was dried using N2 gas at 
40°C, and then reconstituted in 50 μL of IPA:ACN:H2O 
(65:30:5, v/v/v). Reconstituted samples were transferred 
to glass autosampler vials with glass inserts (200 μL) and 
injected into the chromatographic system for analysis. 
LC-MS/MS analyses were performed using an UHPLC 
Dionex3000 (Thermo Fisher Scientific, Germany) coupled 
with an API 5500 triple quadruple mass spectrometer 
(Applied Biosystems/MDS Sciex, Toronto, Canada) 
equipped with an electrospray ion source (ESI) operating 
in polarity switching mode. The injection volume was 
5 μL. Supplementary Figure 1 shows a representative 
extracted ion chromatogram (XIC) of all lipids in a serum 
QC sample. The method validation assays were performed 
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according to the currently accepted US Food and Drug 
Administration (FDA) bioanalytical method validation 
guide [62]. More details about the analytical methods can 
be found in electronic supplementary material.
Principal component analysis
Metabolite levels were transformed into a set 
of values of linearly uncorrelated components. The 
transformation was defined in such a way that the first 
component had the largest possible variance and each 
succeeding component, in turn, had the highest variance 
possible under the constraint that it is orthogonal to (i.e., 
uncorrelated with) the preceding components. First three 
principal components were plotted in two 3D plots in 
Figure 1.
Bioinformatics analysis
Metabolite levels from different platforms were 
analyzed separately to avoid the introduction of platform-
specific biases, due to diverse dynamic ranges, machine-
bound sensitivity and accuracy. Three methods were used 
(described below) to determine their differential over-
representations between diseased and healthy patients. The 
best result came from the consensus of the three outcomes 
and was candidate for downstream pathway and feature 
selection analyses.
Differential metabolomics fingerprint
Sparse PLS-DA
Sparse Partial Least Square Discriminant Analysis 
(sPLS-DA) is a sparse version of the PLS method [63], 
which tackles the classification problem by Linear 
Discriminant Analysis (LDA). It is effectively used to both 
reduce ill-conditioned problems due to multicollinearity 
of high throughput data and to select relevant features 
that maximally discriminate between classes. It takes two 
block data matrices: Y of size (n×q), which is coded with 
dummy variables to indicate the class membership of the 
n samples, and X (n×p), which holds the features to be 
discriminated. PLS is used to simultaneously decompose 
X and Y into latent variables and associated loading 
vectors [64]. We recall here that all the latent variables 
methods (e.g. PLS and Principal Component Regression) 
assume that the studied systems are driven by a small 
number of n-dimensional vectors called latent variables 
and that these might be responsible, or at least be involved 
in, the underlying biological phenomenon [63]. Latent 
variables are linear combinations of the variables. Sparse 
PLS [63], advances from PLS because it incorporates 
variable selection into PLS by penalizing loading vectors 
simultaneously. PLS is principally designed for regression 
problems, it performs well for classification problems also. 
Combined with a LDA method and after selection of the 
wished number of discriminant vectors: H ≤ min (p, K−1), 
where p is the total number of variables and K is the 
number of classes, a p-dimensional data are projected onto 
a H-dimensional space spanned by the first H discriminant 
vectors, also known as dimensions in the case of sPLS, 
and the following function minimized:
min 
ah
, bh
 ‖Mh−ahbʹh‖
2+P
λ
(ah),
where ‖∙‖2 is the Frobenius norm between the current 
cross product matrix (Mh = Xh
TYh) and the loading vectors 
(ah, bh); Pλ(ah) = sign (ah) (ah − λ)+ is the soft-thresholding 
function that approximates the Lasso penalty function 
[65]. In other words, this minimization can be viewed as 
the minimization problem of the regression model (‖∙‖2 
is the sum of squares) penalized by P
λ
(∙) which allows 
a variable selection by approximating the coefficients to 
zero values. The coefficients with values different from 
zero are considered into the model. In particular, in an 
sPLS-DA framework, the selected variables are those 
that best discriminate between two groups. The sPLS-DA 
procedure is implemented in the R package mixOmics 
(http://www.math.univ-toulouse.fr/~biostat/mixOmics). 
The required X matrix was set with metabolite levels, 
while the qualitative response matrix Y was made of 
indicator variables for class membership (0 = diseased, 
1 = healthy). The number of discriminant vectors (or 
components) H was set to 3, in order to plot results in a 
3D space (Figure 1).
Greedy stepwise
This method (also known as the hill-climbing 
attribute selection approach) searches for an optimal 
subset of discriminant metabolites, greedily. It progresses 
forward or backward from the empty and the full sets, 
in order to find the metabolites that maximize a chosen 
evaluation metrics. It does not backtrack but stops when 
the addition/deletion of any remaining metabolite results 
in a decrease in evaluation. The considered metrics is the 
distance between the tumor and control classes (Figure 3).
Genetic search
The GeneticSearch algorithm manipulates 
information proper to genetics like population size, 
number of generations and probabilities of crossover 
and mutations, and works in six steps: initialization, 
evaluation, selection, recombination, mutation and 
replacement. In the initialization phase, GeneticSearch 
starts with a random sample of the candidate feature 
subsets. This sample set is known as population, and each 
candidate feature subset is known as chromosome in the 
GeneticSearch terminology. A chromosome is represented 
as a binary string of zeros and ones, where zero represents 
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the absence of a feature in the chromosome, whereas 
one represents the presence of a feature. The size of a 
chromosome string corresponds to the number of features. 
In the evaluation phase, each chromosome is evaluated 
according to fitness function. In the selection phase, the 
probability of selecting a chromosome is computed by the 
following equation:
where i is a chromosome, fi is the value of the fitness 
function for i, and n is the number of chromosomes, or size 
of the population. Now, the cumulative probability of each 
chromosome qi=∑
i
j=1 pj is computed. A random number r 
is generated between 0 and 1. The first chromosome with 
qi > r is selected, and forms part of the next generation of 
the population. The selection process is repeated n times. 
It is possible that a particular chromosome is selected 
more than once; so the selection phase creates copies of 
chromosomes with high fitness values relative to other 
chromosomes in the population. In the recombination 
phase, two randomly selected chromosomes are combined 
with a cross over probability pc to form offspring 
chromosomes. There are several recombination rules 
in the literature. The most common one is based on 
exchange of bits between chromosomes. In the mutation 
phase, individual bits of a chromosome are flipped with 
a mutation probability pm. In the final phase replacement, 
the initial population is replaced by the new generation, 
which was obtained by selection, recombination and 
mutation. We have applied GeneticSearch implemented in 
Weka (20) for finding the best number of metabolites that 
maximize the separation between diseased and healthy 
patients. We set the following parameters: Population size: 
20; Number of generations: 20; Probability of crossover: 
0.6; Probability of mutation: 0.033; Report frequency: 20; 
Random number seed: 1.
Statistical analysis
Medians and lower-upper quartiles of metabolite 
levels were reported in patients with pancreatic cancer and 
in healthy donors, separately. To validate bioinformatics 
findings (i.e. the three methods for the identification of 
those metabolites which best discriminate pancreatic 
cancer patients from healthy donors), we used the random 
forest analysis (RF) [66] (see Random Forest analysis 
section). The discriminatory ability of each metabolite 
was assessed by estimating the Area Under the Receiver 
Operating Characteristic (ROC) curves (AUC), along with 
their 95%confidence intervals (95%CI), following DeLong 
method [67]. The optimal cut-off was assessed by jointly 
maximizing sensitivity and specificity. Sensitivity and 
specificity, computed at the optimal cut-off, were further 
reported. A p value <0.05 was considered for statistical 
significance. All statistical analyses were performed 
using SAS Release 9.3 (SAS Institute, Cary, NC, USA). 
For the RF analysis, R software (ver. 2.15, package: 
“randomforestSRC”) was used.
Random forest analysis
This appealing method is widely used to perform: 
classification, regression and survival analyses identifying, 
among all available covariates (i.e., all metabolites), the 
ones which were most associated to a specific dependent 
variable of interest (i.e., subject’s status: pancreatic cancer 
or healthy donor). This method is also known to provide 
extremely robust results, especially in context of high 
dimensional dataset. To our purpose, we built 100.000 
trees. The training set used to grow each tree is a 0.632+ 
bootstrap resample of the observations [68]. Trees were 
allowed to grow to their full size without pruning. The best 
split at each node of the tree included into the forest was 
selected from a random subset of covariates. The left-out 
(i.e. “out of bag”) observations were then used to obtain 
the classification error of the considered tree. The RF 
goodness of fit was assessed averaging the individual tree 
classification errors. One of the most relevant strength of 
RF analysis is its capability to impute missing data. Prior 
to splitting a node, missing data for a variable is imputed 
by randomly drawing values from non-missing in-bag data. 
The purpose of this imputed data is to make it possible 
to assign cases to daughter r nodes in the event the node 
is split on a variable with missing data. Imputed data is 
however not used to calculate the split-statistic which uses 
non-missing data only. Following a node split, imputed 
data are reset to missing and the process is repeated until 
terminal nodes are reached. Missing data in terminal nodes 
are imputed using OOB non-missing terminal node data. 
Furthermore, the RF framework estimates the importance 
of each covariate achieved to discriminate the dependent 
variable by looking at how much the classification 
error increases when out of bag data for that variable 
are permuted, while all others are left unchanged. The 
variables’ importance was ranked by assigning to each 
covariate a score based on the ability to predict correctly 
the dependent variable according to the increase of 
classification error when values of that covariate in a node 
were randomly permuted. The importance metric used 
was the Mean Decrease in Accuracy (MDA). The MDA is 
constructed by permuting the values of each variable of the 
test set, recording the prediction and comparing it with the 
un-permuted test set prediction of the variable. Therefore, 
it is the increase in the percentage of times a test set is 
misclassified when the variable is permuted.
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